Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 1, 2001 - Issue 4
Submit an article Journal homepage
168
Views
46
CrossRef citations to date
0
Altmetric
Miscellaneous

Papillomavirus-like particle based vaccines: cervical cancer and beyond

Douglas R Lowy National Cancer Institute, Bethesda, MD, USA, Tel.: +1 301 496 6539; Fax: +1 301 480 5322;, E-mail: [email protected]
&
John T Schiller National Cancer Institute, Bethesda, MD, USA, Tel.: +1 301 496 6539; Fax: +1 301 480 5322;, E-mail: [email protected]
Pages 571-581 | Published online: 23 Feb 2005

Bibliography

  • MUNOZ N: Human papillomavirus and cancer: the epidemiological evidence. j. Viral. (2000) 19:1–5.
  • ZUR HAUSEN H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. I Natl. Cancer Inst. (2000) 92:690–698.
  • STUBENRAUCH F, LAIMINS LA: Humanpapillomavirus life cycle: active and latent phases. Sernin. Cancer Biol. (1999) 9:379–386.
  • BREITBURD F, COURSAGET P: Humanpapillomavirus vaccines. Sernin. Cancer Biol. (1999) 9:431–444.
  • DA SILVA DM, EIBEN GL, FAUSCH SC, et al: Cervical cancer vaccines: emerging concepts and developments. I Cell Physiol. (2001) 186:169–182.
  • LING M, KANAYAMA M, RODEN R, WU TC: Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J. Blamed. Sci. (2000) 7:341–356.
  • ROBBINS JB, SCHNEERSON R, SZU SC: Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. (1995) 171:1387–1398.
  • SCHILLER JT, LOWY DR: Papillomavirus-like particles and HPV vaccine development. Semin. Cancer Biol. (1996) 7:373–382.
  • KIRNBAUER R, BOOY F, CHENG N, LOWY DR, SCHILLER JT: Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad . Li. USA (1992) 89:12180–12184.
  • •First report of papffiomavirus Li VLPs and their ability to induce high titres of neutralising antibodies.
  • HAGENSEE ME, YAEGASHI N, GALLOWAY DA: Self-assembly of human papillomavirus Type 1 capsids by expression of the Li protein alone or by coexpression of the Li and L2 capsid proteins. 1. Viral. (1993) 67:315–322.
  • ROSE RC, BONNEZ W REICHMAN RC, GARCEA RL: Expression of human papillomavirus Type 11 Li protein in insect cells: in vivo and in vitro assembly of viruslike particles. 1. Viral. (1993) 67:1936–1944.
  • HOFMANN K, COOK J, JOYCE J et al: Sequence determination of Human Papillomavirus 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology (1995) 209:506–518.
  • NARDELLI-HAEFLIGER D, RODEN RBS, BENYACOUB J et al: Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella hphimurium elicit mucosal and systemic neutralising antibodies in mice. Inf. Immun. (1997) 65:3328–3336.
  • CHEN XS, CASINI G, HARRISON SC, GARCEA RL: Papillomavirus capsid protein expression in Escherichia colt. Purification and assembly of HPV ii and HPV16 L1.1 Mai Biol. (2001) 307:173–182.
  • TRUS BL, RODEN RBS, GREENSTONE et al.: Novel structural features of bovine papillomavirus capsid revealed by a three dimensional reconstruction to 9A resolution. Nature Struct. Biol. (1997) 4:413–420.
  • KIRNBAUER R, TAUB J, GREENSTONE H et al.: Efficient self-assembly of human papillomavirus Type 16 Li and Li-L2 into virus-like particles. 1. Viral. (1993) 67:6929–6936.
  • VOLPERS C, SCHIRMACHER P, STREECK RE, SAPP M: Assembly of the major and the minor capsid protein of human papillomavirus Type 33 into virus-like particles and tubular structures in insect cells. Virology (1994) 200:504–512.
  • CHRISTENSEN ND, HOPFL R, DIANGELO et al.: Assembled baculovirus-expressed human papillomavirus Type 11 Li capsid protein virus-like particles are recognised by neutralising monoclonal antibodies and induce high titres of neutralising antibodies. 1 Gen. Viral . (1994) 75:2271–2276.
  • MCCARTHY MP, WHITE WI, PALMER-HILL F, KOENIG S, SUZICH JA: Quantitative disassembly and reassembly of human papillomavirus type 11 virus-like particles in vitro. 1. Viral. (1998) 72:32–41.
  • COOK JC, JOYCE JG, GEORGE HA et al.: Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein Li from Saccharomyces cerevisiae. Protein Expr. Purif (1999) 17:477–484
  • HARRO CD, PANG YY, RODEN RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 Li virus-like particle vaccine. 1. Nati Cancer Inst. (2001) 93:284–292.
  • ••Only published clinical trial of a VLPvaccine against an oncogenic HPV type.
  • ROSE RC, WHITE WI, LI M et al.: Human papillomavirus type 11 recombinant Li capsomeres induce virus-neutralising antibodies. 1 Viral. (1998) 72:6151–6154.
  • CHRISTENSEN ND, KIRNBAUER R,SCHILLER JT et al.: Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralising epitopes. Virology (1994) 205:329–335.
  • RODEN RBS, GREENSTONE HL, KIRNBAUER R et al.: In vitro generation and type-specific neutralisation of a human papillomavirus Type 16 virion pseudotype. 1. Viral. (1996) 70:5875–5883.
  • UNCKELL F, STREECK RE, SAPP M: Generation and neutralisation of pseudovirions of human papillomavirus Type 33.1 Viral. (1997) 71:2934–2939.
  • LOWE RS, BROWN DR, BRYAN JT et al.: Human papillomavirus Type 11 (HPV11) neutralising antibodies in the serum and genital mucosal secretions of African green monkeys immunised with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. (1997) 176:1141–1145.
  • WHITE WI, WILSON SD, BONNEZ W ROSE RC, KOENIG S, SUZICH JA: In vitro infection and type-restricted antibody-mediated neutralisation of authentic human papillomavirus Type 16.1 Viral. (1998) 72:959–964.
  • BOSCH FX, MANOS MM, MUNOZ N etal.: Prevalence of human papillomavirus in cervical cancer: a worldwide prospective. 1. Nat. Cancer Inst. (1995) 87:796–802.
  • WALBOOMERS JM, JACOBS MC, MAN 05 MM, BOSCH FX, KUMMER JA, SHAH KV: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. I Pathol. (1999) 189:12–19.
  • BREITBURD F, KIRNBAUER R, HUBBERT NL et al.: Immunisation with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. I Viral. (1995) 69:3959–3963.
  • SUZICH JA, GHIM S, PALMER-HILL et al.: Systemic immunisation with papillomavirus Li protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Li. USA (1995) 92:11553–11557.
  • ••Impressive protection from high dose viruschallenge after low dose VLP vaccination in an oral mucosal model.
  • KIRNBAUER R, CHANDRACHUD L, O'NEIL B et al.: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunisation. Virology (1996) 219:37–44.
  • BAMELLI C, RODEN R, POTTS A, SCHILLER J, DE GRANDE P, NARNELLI-HAEFLIGER D: Nasal immunisation of mice with human papillomavirus type 16 virus-like particles elicits neutralising antibodies in mucosal secretions. 1. Viral. (1998) 8220–8229.
  • LIU XS, ABDUL-JABBAR I, QI YM, FRAZER IH, ZHOU J: Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology (1998) 252:39–45.
  • DUPUY C, BUZONI-GATEL D, TOUZE A, BOUT D, COURSAGET P: Nasal immunisation of mice with human papillomavirus Type 16 (HPV-16) virus-like particles or with the HPV-16 Li gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. j Viral. (1999) 73:9063–9071.
  • ROSE RC, LANE C, WILSON S, SUZICH JA, RYBICKI E, WILLIAMSON AL: Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralising antibodies. Vaccine (1999) 17:2129–2135.
  • EVANS TG, BONNEZ W, ROSE RC et al.: A Phase 1 study of a recombinant virus-like particle vaccine against human papillomavirus Type 11 in healthy adult volunteers. j Infect. Dis. (2001) 183:1485–1493.
  • •Examination of antibody and T-cell responses to VLPs of a genital wart-associated virus.
  • ZHANG LF, ZHOU J, CHEN S et al.: HPV 6b virus like particles are potent immunogens without adjuvant in man. Vaccine (2000) 18:1051–1058.
  • •Only published report of a VLP vaccine trial in patients with an HPV disease.
  • MCNEIL C: HPV vaccines for cervical cancer move toward clinic, encounter social issues. J Natl. Cancer Inst. (1997) 89:1664–1666.
  • BOUVET JP, BELEC L, PIRES R, PILLOT J: Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination. Infect. bran= (1994) 62:3957–3961.
  • VAN GINKEL FW, VANCOTT JL, KIYONO H, MCGHEE JR: Mucosal immunity to human papillomavirus in the female reproductive tract. Papillainavirus Reports (1997) 8:1–10.
  • HERRERO R, HILDESHEIM A, BRATTI C et al.: Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. j Natl. Cancer Inst. (2000) 92:464–474.
  • DE BRUIJN MLH, GREENSTONE HL, VERMEULEN H etal.: Li-specific protection from tumour challenge elicited by HPV16 virus-like particles. Virology (1998) 250:371–376.
  • MULLER M, ZHOU J, REED TD et al.: Chimeric papillomavirus-like particles. Virology (1997) 234:93–111.
  • •Initial report of the Li chimeric VLP technology.
  • PENG S, FRAZER IH, FERNANDO GJ, ZHOU J: Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology (1998) 240:147–157.
  • GREENSTONE HL, NIELAND JD, DE VISSER KE et al.: Chimeric papillomavirus virus-like particles elicit antitumour immunity against the E7 oncoprotein in an HPV16 tumour model. Proc. Nati Acad. Sci. USA (1998) 95:1800–1805.
  • ••Initial report of the L2 chimeric VLPtechnology.
  • SCHAFER K, MULLER M, FAATH S et al.: Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumour protection. Int. j Cancer (1999) 81:881–888.
  • KIVIAT N, KOUTSKY LA, PAAVONEN J: Cervical neoplasia and other STD-related genital tract neoplasias. In: Sexually Transmitted Diseases. Holmes KK, Spalding Mardh P-A, Lemon SM, Piot P, Wasserheit JN (Eds.) (1998).
  • BONTKES HJ, WALBOOMERS JM, MEIJER CJ, HELMERHORST TJ, STERN PL: Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet (1998) 351:187–188.
  • BRADY CS, BARTHOLOMEW JS, BURT DJ et al.: Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens (2000) 55:401–411.
  • KOOPMAN LA, CORVER WE, VAN DER SLIK AR, GIPHART MJ, FLEUREN GJ: Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. j Exp. Med. (2000) 191:961–976.
  • RAMSHAW IA, RAMSAY AJ: The prime-boost strategy: exciting prospects for improved vaccination. hninunal. Today (2000) 21:163–165.
  • NIELAND JD, DA SILVA DM, VELDERS MP etal.: Chimeric papillomavirus virus-like particles induce a murine self- antigen-specific protective and therapeutic antitumour immune response. Cell Biachent (1999) 73:145–152.
  • ••Chimeric VLP mediated tumourimmunotherapy against a tumour antigen peptide that is tolerating when administered as a free peptide.
  • BACHMANN ME ZINKERNAGEL RIVI: Neutralising antiviral B cell responses. Ann. Rev Innnunal. (1997) 15:235–270.
  • FEHR T, SKRASTINA D, PUMPENS P, ZINKERNAGEL RIVI: T cell-independent Type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. USA (1998) 95:9477–9481.
  • KRATZ PA, BOTTCHER B, NASSAL M: Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Nati Acad. Sci. USA (1999) 96:1915–1920.
  • SIEMASKO K, CLARK MR: The control and facilitation of MHC class II antigen processing by the BCR. Curr. Opin. hninunal. (2001) 13:32–36.
  • YEWDELL JW, NORBURY CC, BENNINK JR: Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumours, transplants, and vaccines. Adv. Innnunal. (1999) 73:1–77
  • ZHOU J, GISSMANN L, ZENTGRAF H, MULLER H, PICKEN M, MULLER M: Early phase in the infection of cultured cells with papillomavirus virions. Virology(1995) 214:167–176.
  • LENZ P, DAY PM, PANG YS etal.: Papillomavirus-like particles induce acute activation of dendritic cells. j Innnunal. (2001) 166:5346–5355.
  • •Provides a mechanistic explanation for the high intrinsic immunogenicity of papffiomavirus VLPs.
  • RUDOLF MP, FAUSCH SC, DA SILVA D, KAST WM: Human dendritic cells are activated by chimeric human papillomavirus Type 16 virus-like particles and induce epitope-specific human T cell responses in vitro. I Innnunal. (2001) 166:5917–5924.
  • •Provides a mechanistic explanation for the high intrinsic immunogenicity of papillomavirus VLPs.
  • GLENNIE MJ, JOHNSON PW: Clinical trials of antibody therapy. Innnunal. Today (2000) 21:403–410.
  • HERTZ M, NEMAZEE D: Receptor editing and commitment in B-lymphocytes. Curr. Opin. Immune]. (1998) 10:208–213.
  • CHEN X, KEARNEY JF: Generation and function of natural self-reactive B lymphocytes. &min. Innnunal. (1996) 8:19–27.
  • DALUM I, JENSEN MR, HINDERSSON P, ELSNER HI, MOURITSEN S: Breaking of B cell tolerance toward a highly conserved self protein. j Innnunal. (1996) 157:4796–4804.
  • FANG W, WEINTRAUB BC: et al: Self-reactive B lymphocytes overexpressing Bcl-XL escape negative selection and are tolerised by clonal anergy and receptor editing. Immunity (1998) 9:35–45.
  • RATHMELL JC, FOURNIER S, WIENTRAUB BC, ALLISON JP, GOODNOW CC: Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4+ T cells. j. Exp. Med. (1998) 188:651–659.
  • ALBERT LJ, INMAN RD: Molecular mimicry and autoimmunity. N Erigl Med. (1999) 341:2068–2074.
  • DALUM I, JENSEN MR, GREGORIUS K, THOMASEN CM, ELSNER HI, MOURITSEN S: Induction of cross-reactive antibodies against a self protein by immunisation with a modified self protein containing a foreign T helper epitope. Mol. Immunol. (1997) 34:1113–1120.
  • TALWAR GP, SHARMA NC, DUBEY SK et al.: Isoimmunisation against human chorionic gonadotropin with conjugates of processed b-subunit of the hormone and tetanus toxoid. Proc. Nat. Acad. Sci. (1976) 73:218–222.
  • DALUM I, BUTLER DM, JENSEN et al.: Therapeutic antibodies elicited by immunisation against TNF-alpha. Nature Biotechnol. (1999) 17:666–669.
  • •Proof of concept demonstration that vaccine-induced antibodies to a central self-antigen can elicit a therapeutic response in mice.
  • TALWAR GP, SINGH 0, PAL R et al.: A vaccine that prevents pregnancy in women. Proc. Natl. Acad. Sci. USA (1994) 91:8532–8536.
  • •An interesting clinical trial of a first generation auto-antibody inducing vaccine.
  • BACHMANN MF, ROHRER UH, KUNDIG TM, BURKI K, HENGARTNER H, ZINKERNAGEL RM: The influence of antigen organisation on B cell responsiveness. Science (1993) 262:1448–1451.
  • CHACKERIAN B, LOWY DR, SCHILLER JT: Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc. Natl. Acad. Li. USA (1999) 96:2373–2378.
  • •The first demonstration that B-cell tolerance to a cell surface central antigen can be effectively broken by display of the target peptide on the surface of a VLP.
  • SLOVIN SF, RAGUPATHI G, ADLURI et al.: Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA (1999) 96:5710–5715.
  • KUDRYASHOV V, GLUNZ PW, WILLIAMS LJ, HINTERMANN S, DANISHEFSKY SJ, LLOYD KO: Toward optimised carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewisy conjugates in mice. Proc. Nail. Acad. Sci. USA (2001) 98:3264–3269.
  • DA SILVA D, VELDERS MP, RUDOLF MP SCHILLER JT, KAST WM: Papillomavirus virus-like particles as anticancer vaccines. Curr. Opin. Mol. Therapeutics (1999) 1:82–88.

Website

  • www.hpv2000.com 18th International Papillomavirus Conference

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.